Answers are grounded in this paper and cite their sources.
Multi-cohort study demonstrates enhanced prediction of pathologic complete response in breast cancer patients, suggesting utility for guiding pre-treatment therapy choices.
Neoadjuvant chemotherapy (NAC) can eliminate all invasive cancer in some breast cancer patients, achieving a pathologic complete response (pCR) that is associated with a better prognosis. Prediction of pCR from pre-treatment radiology imaging is challenging but could provide immense value in the treatment planning. We propose a novel multimodal deep learning approach that combines pre-treatment dynamic contrast-enhanced MRI and clinical data for predicting pCR before chemotherapy. It is the first to integrate attention-based multiple instance learning technique for slice aggregation and a self-supervised contrastive objective to align image and clinical embeddings. Our model was trained on 1491 patients across four cohorts with expert tumor segmentations. On a stratified hold-out test set, the multimodal model achieved AUC 0.83 (95% CI 0.78-0.89), outperforming late fusion without contrastive alignment and single-modality baselines. These results, obtained on the largest multi-cohort breast MRI dataset comprising four clinical trials, underscore the potential of contrastive learning-based multimodal AI models to improve pCR prediction. With further validation, our proposed approach could support pre-treatment decision-making by identifying patients likely to achieve pCR and those who may benefit from alternative regimens.
No takes yet. Share an insight, caveat, or question.
Goyal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: